Is BALT or JNJ a better dividend investment in 2026?

BALT currently yields 5.98% with a 5% 5-year dividend growth rate. JNJ yields 2.13% with 5.8% growth. The better choice depends on your goal: BALT offers higher current income.

What is the dividend yield difference between BALT and JNJ?

BALT has a forward dividend yield of 5.98% ($2.00/share annually). JNJ yields 2.13% ($5.20/share annually). The yield gap is 3.85 percentage points.

Home › Compare › BALT vs JNJ

BALT vs JNJ: Dividend Comparison 2026

BALT yields 5.98% · JNJ yields 2.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 JNJ wins by $606.00 in total portfolio value· pulled ahead in Year 10

INVESTMENT

TIME HORIZON10 years

BALT

● Live price

5.98%

Share price

$33.47

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$29.7K

Annual income

$874.75

Full BALT calculator →

JNJ

Johnson & Johnson

● Live price

2.13%

Share price

$244.44

Annual div

$5.20

5Y div CAGR

28%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.3K

Annual income

$4,689.40

Full JNJ calculator →

Portfolio growth — BALT vs JNJ

📍 JNJ pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	BALT	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, BALT + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

BALT pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BALT

Annual income on $10K today (after 15% tax)

$507.99/yr

After 10yr DRIP, annual income (after tax)

$743.54/yr

JNJ

Annual income on $10K today (after 15% tax)

$180.82/yr

After 10yr DRIP, annual income (after tax)

$3,985.99/yr

At 15% tax rate, JNJ beats the other by $3,242.45/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BALT + JNJ for your $10,000?

BALT: 50%JNJ: 50%

100% JNJ50/50100% BALT

Portfolio after 10yr

$30.0K

Annual income

$2,782.08/yr

Blended yield

9.28%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

BALT

No analyst data

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

-6.4% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BALT buys

JNJ buys

No recent congressional trades found for BALT or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricBALTJNJ

Forward yield	5.98% ✓	2.13%
Annual dividend / share	$2.00	$5.20 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	28% ✓
Portfolio after 10y	$29.7K	$30.3K ✓
Annual income after 10y	$874.75	$4,689.40 ✓
Total dividends collected	$7.4K	$15.4K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: BALT vs JNJ ($10,000, DRIP)

Year	BALT Portfolio	BALT Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1	$11,298	$597.64	$10,592	$272.30	+$706.00 → BALT
2	$12,719	$631.02	$11,289	$357.73	+$1.4K → BALT
3	$14,274	$663.96	$12,123	$472.89	+$2.2K → BALT
4	$15,969	$696.35	$13,141	$629.86	+$2.8K → BALT
5	$17,815	$728.10	$14,408	$846.81	+$3.4K → BALT
6	$19,821	$759.12	$16,021	$1,151.60	+$3.8K → BALT
7	$21,998	$789.36	$18,122	$1,588.22	+$3.9K → BALT
8	$24,357	$818.73	$20,930	$2,228.20	+$3.4K → BALT
9	$26,909	$847.21	$24,792	$3,191.91	+$2.1K → BALT
10← crossover	$29,668	$874.75	$30,274	$4,689.40	$606.00 → JNJ

BALT vs JNJ: Complete Analysis 2026

BALT — Stock

The Innovator Defined Wealth Shield ETF seeks to track the return of the SPDR S&P 500 ETF Trust (SPY), to a cap, and provide a measure of downside protection by seeking to buffer investors against losses. The ETF targets a 20% buffer every 3-month outcome period. The ETF can be held indefinitely, resetting at the end of each outcome period.

Full BALT Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

📬

Get this BALT vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BALT vs SCHD BALT vs JEPI BALT vs O BALT vs KO BALT vs MAIN BALT vs ABBV BALT vs MRK BALT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.